Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
4.1
Journals
Microorganisms
Special Issues
Infectious Diseases: New Approaches to Old Problems 3.0
share announcement

Infectious Diseases: New Approaches to Old Problems 3.0

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Public Health Microbiology".

Deadline for manuscript submissions: 15 January 2025 | Viewed by 3222

Special Issue Editors

Dr. Monica Cartelle Gestal

E-Mail Website
Guest Editor
Microbiology and Immunology Department, Louisiana State University Health Sciences Center, Shreveport, LA, USA
Interests: microbiology; infectious diseases; bordetella; vaccines
Special Issues, Collections and Topics in MDPI journals
Dr. Eva Torres-Sangiao

E-Mail Website
Guest Editor
Clinical Microbiology Laboratory, University Hospital Marqués de Valdecilla, Researh Institute IDIVAL, 39001 Santander, Spain
Interests: system biology; immunoproteome; infectious diseases; sexual transmission diseases; mass spectrometry
Special Issues, Collections and Topics in MDPI journals
Dr. Nelson C. Soares

E-Mail Website
Guest Editor
College of Pharmacy, Department of Medicinal Chemistry, Sharjah University, Sharjah, United Arab Emirates
Interests: proteomics; mass spectrometry; metabolomics; microbiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the continuation of our previous Special Issue, entitled “Infectious Diseases: New Approaches to Old Problems 2.0”.

After living in a time of widespread concern regarding COVID-19, the threat still remains, with infectious diseases one of the leading causes of death worldwide. Pathogens are responsible for countless outbreaks of disease among humans, with significant impacts on public health as well as the economy. The increase in antibiotic resistance is a well-known phenomenon that has begun to form a new pandemic; nevertheless, the concept of One Health has hallmarked the lack of prevention in control in other areas that have great implications for human health. Also, one trait common to most pathogens is their ability to modulate, manipulate, and escape host immune responses. The scientific community must develop innovative diagnostics that provide sample-to-answer techniques to readily analyze on-site data in the field, as well as new therapeutic alternatives. Therefore, immunomodulation approaches, such as adjuvants, therapies, and vaccines, appear to be the most compelling and promising methods with which to enhance immune responses. Importantly, bacteria, along with viruses and parasites, are great hazards and a challenge to prevent as well as treat.

The aim of this Special Issue is to unite several fields of research to approach the problem from a One Health perspective. The need for this Issue emerges because of the lack of strategies and solutions to overcome infectious diseases in the framework of technology and the interconnected world. It will also be a platform on where novel strategies for vaccine and therapeutic development will be provided, focusing on immunomodulation. 

Dr. Monica Cartelle Gestal
Dr. Eva Torres-Sangiao
Dr. Nelson C. Soares
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • infectious diseases
  • antibiotic resistance
  • vaccines and therapies
  • biomarkers and diagnosis
  • mass spectrometry
  • immunomodulation
  • inflammation
  • systems biology
  • metabolomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1845 KiB  
Article
Effects of Thermally-Assisted and High-Pressure Processing on Background Microbiota and the Listeria monocytogenes Load of a Minimally Processed Commodity
by Ranju Kafle and Aliyar Cyrus Fouladkhah
Microorganisms 2024, 12(9), 1858; https://doi.org/10.3390/microorganisms12091858 - 7 Sep 2024
Viewed by 614
Abstract
The current study investigated the impact of treatments with elevated hydrostatic pressure (500 MPa) for inactivation of Listeria monocytogenes on smoked rainbow trout (Oncorhynchus mykiss) at high and low inoculation levels. The temperature values of the trials were set at 4.4 [...] Read more.
The current study investigated the impact of treatments with elevated hydrostatic pressure (500 MPa) for inactivation of Listeria monocytogenes on smoked rainbow trout (Oncorhynchus mykiss) at high and low inoculation levels. The temperature values of the trials were set at 4.4 and 60.0 °C, adjusted with a circulating water bath connected to a stainless steel jacket surrounding the pressure processing chamber. Before pressure processing, the counts (selective counts of PALCAM, mean ± SD) of L. monocytogenes were 6.45 ± 0.1 log CFU/g and were reduced (p < 0.05) to 3.72 ± 0.3, and <1.48 ± 0.8 log CFU/g after 10 min of treatment at 4.4 and 60.0 °C, respectively. Treatments of low inoculation level samples were similarly efficacious and resulted in a reduction (p < 0.05) of the pathogen to 1.62 ± 0.3 and <0.82 ± 0.0 log CFU/g for treatments at 4.4 and 60.0 °C, respectively. At 4.4 °C, linear D-value and non-linear kmax1 were 8.68 and 0.50, and 5.81 and 2.41 for high-inoculation and low-inoculation samples, respectively. Application of hydrostatic pressure at 500 MPa at cold and elevated temperatures was efficacious for up to 5.03 log CFU/g reduction of L. monocytogenes, illustrating the potential for further adaptation of this technology. Full article
(This article belongs to the Special Issue Infectious Diseases: New Approaches to Old Problems 3.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 779 KiB  
Review
Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics
by Camilia Metadea Aji Savitri, Kartika Afrida Fauzia, Ricky Indra Alfaray, Hafeza Aftab, Ari Fahrial Syam, Masrul Lubis, Yoshio Yamaoka and Muhammad Miftahussurur
Microorganisms 2024, 12(10), 1986; https://doi.org/10.3390/microorganisms12101986 - 30 Sep 2024
Viewed by 757
Abstract
Helicobacter pylori (H. pylori) is a bacterium known to be associated with a significant risk of gastric cancer in addition to chronic gastritis, peptic ulcer, and MALT lymphoma. Although only a small percentage of patients infected with H. pylori develop gastric [...] Read more.
Helicobacter pylori (H. pylori) is a bacterium known to be associated with a significant risk of gastric cancer in addition to chronic gastritis, peptic ulcer, and MALT lymphoma. Although only a small percentage of patients infected with H. pylori develop gastric cancer, Gastric cancer causes more than 750,000 deaths worldwide, with 90% of cases being caused by H. pylori. The eradication of this bacterium rests on multiple drug regimens as guided by various consensus. However, the efficacy of empirical therapy is decreasing due to antimicrobial resistance. In addition, biofilm formation complicates eradication. As the search for new antibiotics lags behind the bacterium’s ability to mutate, studies have been directed toward finding new anti-H. pylori agents while also optimizing current drug functions. Targeting biofilm, repurposing outer membrane vesicles that were initially a virulence factor of the bacteria, phage therapy, probiotics, and the construction of nanoparticles might be able to complement or even be alternatives for H. pylori treatment. This review aims to present reports on various compounds, either new or combined with current antibiotics, and their pathways to counteract H. pylori resistance. Full article
(This article belongs to the Special Issue Infectious Diseases: New Approaches to Old Problems 3.0)
►▼ Show Figures

Figure 1

23 pages, 1316 KiB  
Review
Addressing Sexually Transmitted Infections Due to Neisseria gonorrhoeae in the Present and Future
by Julia Colón Pérez, Rosa-Antía Villarino Fernández, Adrián Domínguez Lago, María Mercedes Treviño Castellano, María Luisa Pérez del Molino Bernal, Sandra Sánchez Poza and Eva Torres-Sangiao
Microorganisms 2024, 12(5), 884; https://doi.org/10.3390/microorganisms12050884 - 28 Apr 2024
Viewed by 1559
Abstract
It was in the 1800s when the first public publications about the infection and treatment of gonorrhoea were released. However, the first prevention programmes were only published a hundred years later. In the 1940s, the concept of vaccination was introduced into clinical prevention [...] Read more.
It was in the 1800s when the first public publications about the infection and treatment of gonorrhoea were released. However, the first prevention programmes were only published a hundred years later. In the 1940s, the concept of vaccination was introduced into clinical prevention programmes to address early sulphonamide resistance. Since then, tons of publications on Neisseria gonorrhoeae are undisputed, around 30,000 publications today. Currently, the situation seems to be just as it was in the last century, nothing has changed or improved. So, what are we doing wrong? And more importantly, what might we do? The review presented here aims to review the current situation regarding the resistance mechanisms, prevention programmes, treatments, and vaccines, with the challenge of better understanding this special pathogen. The authors have reviewed the last five years of advancements, knowledge, and perspectives for addressing the Neisseria gonorrhoeae issue, focusing on new therapeutic alternatives. Full article
(This article belongs to the Special Issue Infectious Diseases: New Approaches to Old Problems 3.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop